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Abstract
Background. Although the survival of children with soft tissue sarcoma (STS) has improved considerably, the outcome
of patients with metastatic disease, and those with primary tumours of the extremities or parameningeal sites remains
disappointing. We describe the clinical outcome of an ifosfamide-based regimen with local therapy directed only to
children who failed to achieve a complete response to initial chemotherapy.
Patients and Methods Twenty-one children with STS (16 rhabdomyosarcoma) who presented with unresectable tumours
were treated with ® ve courses of ifosfamide (9 g/m
2) and etoposide (600 mg/m
2). Patients who did not achieve a complete
response then received local therapy. Chemotherapy with ifosfamide combined with etoposide, vincristine (1.5 mg/m
2 and
doxorubicin (60 mg/m
2) or vincristine and actinomycin D (1.5 mg/m
2) was continued for one year.
Results and Discussion. Objective responses to ® ve courses of ifosfamide and etoposide were seen in all patients. Disease
free survival (DFS) at a median follow up of 59 months was 57% (95% CI 29± 75%). The DFS of children who received
local therapy was 89% compared with 33% in those who received chemotherapy alone (p 5 0.027). Locoregional
recurrences did not occur in children who received radiotherapy to the site of the primary tumour. Ifosfamide-based
chemotherapy does not reduce the incidence of loco-regional recurrence in children who do not receive local therapy.
Key words: soft tissue sarcoma, chemotherapy, local control.
Introduction
Soft tissue sarcomas (STS) constitute up to 6% of
all childhood malignancies. The overall survival for
children with rhabdomyosarcoma (RMS), the most
common STS, has increased considerably over the
last twenty-® ve years to 70%.
1 This improvement
follows the introduction of multiagent chemo-
therapy combined with effective treatment of re-
sidual tumour masses with either surgery,
radiotherapy (RT), or a combination of both.
2,3 The
outcome of several subgroups of patients with RMS
remains disappointing. Features consistent with a
poor prognosis include the presence of metastatic
disease,
3 high proliferative activity
4 and the presence
of the [t(2;13)(q35;q14)] translocation.
5 Alveolar
histology, previously thought of as being associated
with treatment resistance, may be of lesser
signi® cance following the intensi® cation of chemo-
therapy regimens.
3 The primary site of disease is
also important with paratesticular and orbital tu-
mours having a more favourable prognosis than
those located in the parameningeal regions of the
head and neck or the extremities.
2,3
The rarity of non-RMS STS has led to uncer-
tainty over the optimal treatment for these tumours.
Although generally considered to be less chemosen-
sitive than RMS, many are treated in a similar
manner with greater emphasis being placed on local
disease control.
6 Two STS staging systems have
been widely reported in the literature. The post-op-
erative clinical grouping strategy of the Intergroup
Rhabdomyosarcoma Study Group (IRS) has been
criticised as being strongly in¯ uenced by the surgical
approach employed in each case. An alternative
approach has been adopted by the International
Society of Paediatric Oncology (SIOP), which allo-
cates treatment according to stage and post-surgical
status. One consequence of the improved survival of
children with STS has been an increasing awareness
of the long term sequelae of treatment. These in-
clude the adverse effects of RT on growing bones,
teeth, eyes, bladder and the pituitary gland, particu-
larly in very young children.
7± 11 The introduction of
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Table 1. Patient details
Age
Patient (years) Tumour Site IRS TNM
1 0.6 RMS(e) infratemporal fossa* III T2bN0M0
2 2 RMS(e middle ear* III T2bN0M0
3 2 RMS(l) paratesticular II T1bN0M0
4 2 RMS(e) scalp III T1bN1M0
5 3 RMS(e) chest wall III T2bN0M0
6 3 RMS(e) middle ear* III T1bN0M0
7 3 RMS(e) intratemporal fossa* III T2bN1M0
8 4 RMS(sa) chest wall III T2bN1M0
9 4 RMS(e) genitourinary III T2bN0M0
10 4 RMS(e) middle ear* III T2bN0M0
11 5 RMS(e) orbit III T1aN0M0
12 6 RMS(e) orbit III T1abN0M0
13 6 RMS(e) retroperitoneal III T2bN0M0
14 7 RMS(l) soft palate III T1abN0M0
15 8 RMS(a) forearm III T1bN1M1
16 14 RMS(e) genitourinary III T2bN0M0
17 0.6 peripheral nerve pelvis III T2bN0M0
sheath tumour
18 2 epithelioid face III T1aN1M0
schwannoma
19 5 angiosarcoma pelvis III T2bN1M0
20 6 granular cell pelvis III T2bN1M0
tumour
(myoblastoma)
21 12 epitheliod hand II T1aN1M0
sarcoma
IRS: Intergroup Rhabdomyosarcoma Study clinical grouping.







more intensive chemotherapy has been ac-
companied by the appearance of second malignan-
cies and may lead to a higher incidence of
infertility.
12,13
Despite improved survival the optimum combi-
nation of chemotherapy and timing of local disease
control remains uncertain. Here we report the re-
sults of a ifosfamide-based treatment regimen in
children who presented with tumours which were
not completely resectable at presentation without
mutilating surgery.
Patient details
Twenty-one children (8 female) with STS (16
RMS) were treated between November 1987 and
January 1994 using the treatment protocol de-
scribed below (Table 1). The median age at diag-
nosis was 4 years (range 0.6± 14 years). Eighteen
children (85%) presented with unresectable disease,
either as a consequence of the site of the primary
tumour or as the result of locoregional or distant
spread. Three patients (14%) had macroscopic/mi-
croscopic evidence of tumour following primary
surgery (Nos. 3, 14 and 21). A single patient had
widespread bone and bone marrow metastases at
diagnosis (No. 15). No other patient had evidence
of disseminated disease at presentation. Five chil-
dren with RMS had primary tumours located at
parameningeal sites, one of whom had evidence of
direct intracranial extension on computed tomo-
graphic Imaging (No. 10). None of these patients
had malignant cells present in a cytospin prep-
aration of their cerebrospinal ¯ uid. Two RMS tu-
mours exhibited alveolar histology and the
translocation [t(2;13)(q35;q14)] was identi® ed in
metaphase preparations from both (Nos. 8 and 15).
An identical translocation was also detected in an
epithelioid schwannoma (No. 18). No patient had
received previous chemotherapy or RT.
Treatment protocol
All children initially received ® ve courses of Ifos-
famide (3 g/m
2) combined with etoposide (200 mg/
m
2) on each of three consecutive days (IE). This
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Fig. 1. Outline of treatment regimen.
Protocol violations
Both children with orbital RMS achieved a CR with
® ve courses of IE (Nos. 11 and 12). In view of this
response, and the favourable prognosis of this tu-
mour site a further four courses of IE only were
administered. Another patient underwent tumour
resection after 10 courses of chemotherapy. No
viable tumour was found and therapy was discontin-
ued in accordance with parental wishes (No. 17).
Local therapy
After completing ® ve courses of IE, 13 children
(62%) (nine RMS) had residual macroscopic dis-
ease (Table 2). Six of these (four RMS) received RT
at a median dose of 45 Grays (range 43± 50 Grays)
to the tumour bed with margins of at least 2 cm.
The patient with an intracranial extension of her
parameningeal RMS received an additional 30
Grays whole brain RT. Six children underwent sur-
gical resection of residual tumour.
Results
Response
Re-evaluation following ® ve courses of chemo-
therapy demonstrated that all patients had objective
responses to IE (see Table 2). There were ® ve CRs
(four RMS) (24%) and 13 PRs (10 RMS) (62%).
The Kaplan-Meier estimate of disease free survival
(DFS) at a median follow up of 59 months (range
35± 115 months) was 57% (95% CI 29± 75%).
16
DFS in children who received appropriate local
therapy, either surgery or RT, was 89% at 3 years
compared to only 33% in those who received
chemotherapy alone (p5 0.027, Log-rank test).
Two children who developed recurrent disease with-
out previously having received de® nitive local ther-
apy were treated with further chemotherapy and
RT. One is disease-free 17 months from recurrence
(No 14). The second patient developed a further
local recurrence 6 months later and is presently
receiving palliative chemotherapy only (No 4).
Disease progression
In all there were ® ve locoregional recurrences
(24%). Four of these children were receiving treat-
ment for RMS. A single patient developed pul-
monary metastases after completing treatment. The
patient with multiple bony metastases from a RMS
improved during therapy but deteriorated upon its
completion. Of the ® ve children who achieved a CR
with chemotherapy none received de® nitive local
therapy and two have subsequently developed dis-
ease recurrence at the site of the primary tumour.
One patient who was receiving treatment for a
chest wall RMS accompanied by extensive mediasti-
nal and para-aortic lymphadenopathy achieved a
to reassessment of the tumour. During these and
subsequent courses Ifosfamide was administered as
a continuous intravenous infusion over 72 hours
accompanied by an equivalent dose of mesna
included in the hydration ¯ uid which was given at
3 l/m
2/day. Mesna hydration was continued for
12 hours after the infusion of ifosfamide was
complete. Following ® ve courses of IE further
chemotherapy consisted of rotating courses of
Ifosfamide (9 g/m
2) with vincristine (1.5 mg/m.3)
and actinomycin D (1.5 mg/m
2 (IVA), ifosfamide
with vincristine (1.5 mg/m
2) and doxorubicin
(20 mg/m
2) administered over 6 hours on each of
three consecutive days (IVAd) and further courses
of IE (Fig. 1). Chemotherapy was administered at
three weekly intervals or delayed until the neutrophil
count had recovered to 1 3 10
9/l and the platelet
count was greater than 100 3 10
9/l. Total treatment
duration was one year. Chemotherapy was
continued during RT but courses of IVA or IVAd
were replaced with IE, and the order of subsequent
courses was rearranged to ensure that each
child received the same cumulative dose of each
drug. In total, 21 children received a median of 15
courses of chemotherapy (range 9± 18 courses) com-
prising a median of 126 g/m
2 of ifosfamide (range
81± 162 g/m
2) and a median of 240 mg/m
2 of dox-
orubicin (range 0± 240 mg/m
2. Children with para-
meningeal RMS received eight doses of intrathecal
chemotherapy comprising cytosine arabinoside (30
mg), hydrocortisone (30 mg) and methotrexate
(12.5 mg). In all cases response was evaluated by
computerised axial tomographic scans with en-
hancement.
Responses were de® ned as follows: Complete
Response (CR) resolution of all apparent tumour,
Partial Response (PR) more than 50% decrease
in tumour dimensions as measured by the sum of
the products of the maximal perpendicular diame-
ters of all measurable lesions and Stable Disease less
than 50% decrease in tumour dimensions or no
change.174 S. M. Yule et al.
Table 2. Treatment outcome
Response to
® ve courses Local
Patient of IE therapy Outcome GFR NTX
1 PR none locoregional NP NP
recurrence
2 PR RT septic death NP NP
3 NE surgery disease free 76 9
4 CR none locoregional NP NP
recurrence
5 PR surgery pulmonary NP NP
metastases
6 PR RT disease free 81 6
7 PR RT disease free 81 5
8 PR RT* locoregional NP NP
recurrence
9 PR surgery disease free 98 1
10 PR RT disease free 76 3
11 CR none disease free 81 7
12 CR none disease free 75 2
13 CR none disease free 67 7
14 NE surgery locoregional 68 5
recurrence
15 PR none progressive NP NP
disease
16 PR none septic death NP NP
17 PR surgery disease free 74 5
18 CR none locoregional 87 10
recurrence
19 PR surgery disease free 100 4
20 PR RT disease free 68 8
21 NE surgery disease free 59 8
Patients evaluated after ® ve courses of ifosfamide/etoposide (IE). Follow up measurements




GFR: Glomerular ® ltration rate (ml/min/1.72 m2).
NTX: nephrotoxicity score (Skinner et al. 1993).
0 5 no nephrotoxicity.
1± 3 5 mild nephrotoxicity.
4± 7 5 moderate nephrotoxicity.
$ 8 5 severe nephrotoxicity.
*radiotherapy to affected lymph nodes only.
complete disappearance of his primary tumour and
a considerable reduction in the size of his
lymphadenopathy with ® ve courses of IE (No. 8). In
the absence of persisting disease at the primary site
and in order to limit cardiac exposure, RT was
administered to the site of his involved lymph nodes
only. He developed a recurrence at the site of his
primary tumour two months after completing
chemotherapy. Another patient who presented with
a parameningeal RMS at the age of 1 year achieved
a PR with ® ve courses of IE (No. 1). The likelihood
of severe long-term post-RT sequelae in this child
was considered to be high. A repeat biopsy found no
evidence of viable tumour and no local therapy was
administered. This child developed a locoregional
recurrence ® ve months after completing chemo-
therapy. Locoregional recurrences did not occur in




A total of 293 courses of chemotherapy were admin-
istered, 171 (58%) of these were complicated by an
admission for fever in the presence of neutropenia.
There were 41 independent septicaemic episodes
with a variety of infecting bacteria. Twenty (49%) of
these proven infections were related to indwelling
central venous catheter colonization. Two children
developed episodes of microbiologically proven fun-
gal septicaemia. There were two deaths from over-
whelming sepsis. Common toxicity criteria grade 3
thrombocytopenia and grade 4 neutropenla were
invariable following chemotherapy. HaematologicalSoft tissue sarcoma treatment protocol in children 175
and infective toxicity was unaffected by concurrent
RT but was more severe during the second 6
months of treatment. All children required intermit-
tent support with blood products.
Gastrointestinal
Chemotherapy induced nausea and vomiting were
manageable with ondansetron combined with dex-
amethasone. Weight loss during therapy was in-
variable and seven children (33%) required
nasogastric alimentation. Constipation and anal
® ssures were common.
Renal
Fifteen children were available for renal function
testing 2 years from diagnosis. The median
glomerular ® ltration rate was 76 mils/min/1.73m
2
(range 59± 100 mls/min/1.73m
2) (see Table 2). A
combined score of both glomerular and tubular
function in these children produced a median value
of 5 (range 1± 10), with 4 to 7 representing moderate
nephrotoxicity and greater than or equal to 8 severe
nephrotoxicity.
14 Detailed description of the extent
of both glomerular and tubular dysfunction In many
of these patients has been presented elsewhere.
15
Other toxicities
Whilst increased somnolence during IF therapy was
common, this rarely extended beyond 50% of wak-
ing hours (WHO Grade 2). Severe somnolence and
confusion followed three courses of chemotherapy
in three different patients (WHO Grade 3). In each
case neurological impairment resolved sponta-
neously and did not recur. Grade 3 neurotoxicity
was not considered an indication for adjusting sub-
sequent chemotherapy. Local reactions to RT were
uncommon and no more severe than expected de-
spite continuing chemotherapy with IE. Cardiac
toxicity was monitored using echocardiography and
no patient has a persistent fractional shortening of
less than 30%. Haemorrhagic cystitis requiring ad-
mission and platelet support occurred in two chil-
dren. The patient who received cranial irradiation
has persisting alopecia. Following chemotherapy
one patient developed a symptomatic oesophageal
stricture as a consequence of severe mucositis, and
continues to require regular dilatation. Two chil-
dren who received RT for a RMS of the middle ear
have marked unilateral hearing loss. There have
been no second malignancies.
Discussion
STS of childhood represent a diverse group of tu-
mours which differ widely in terms of their malig-
nant potential and treatment response. RMS, the
largest single member of this group, is increasingly
recognised to be a spectrum of different diseases
rather than a single entity. This is re¯ ected in the
variable prognosis for RMS at different anatomical
sites.
2,3 The location of the primary tumour does not
provide a complete explanation as to why one child
fares well with existing therapy, whilst another pa-
tient with a histological and anatomically identical
tumour develops recurrent disease. In the future this
issue may be clari® ed by molecular studies.
17 The
presence of a chromosomal translocation
[t(2;13)(q35;q14)] in RMS has been linked with the
presence of disseminated disease at diagnosis and a
poor response to treatment.
18 This translocation was
detected in three patients, all of whom died from
recurrence.
Here we report the use of an ifosfamide-based
treatment protocol in the management of all non-re-
sectable sarcomas. At its inception this programme
was designed to improve cure rates In children who
presented with tumours which were unresectable
without mutilating surgery. Five courses of IE were
given to shrink the tumour mass prior to de® nitive
local therapy. Chemotherapy was continued for 1
year in an effort to eradicate systemic micrometas-
tases. The conclusions that can be drawn from these
results are limited by both the small number of
patients and the heterogeneity of the tumours
treated. The Introduction of Ifosfamide as the alky-
lating agent `backbone’ of this regimen followed
several promising reports of its ef® cacy In the treat-
ment of STS and possible superiority over cy-
clophosphamide.
19± 26 An earlier report
demonstrated the safety of 9 g/m
2 of ifosfamide
when administered over three days in children with
normal renal function.
27 Etoposide and ifosfamide
are synergistic in vitro and the combination has
excellent activity against STS in phase II studies.
28
This activity was evident in the 100% response rate
to ® ve courses of IE. The sensitivity of STS to
vincristine, actinomycin D and doxorubicin is well
established.
29± 31
Actinomycin D and doxorubicin are known ra-
diosensitisers and the administration of either of
these drugs during RT is accompanied by an in-
crease in radiation-induced local tissue damage.
32
This has led to both drugs being avoided during and
immediately following RT. Although several studies
have shown that etoposide inhibits the repair of
sub-lethal radiation damage in experimental systems
there is little evidence of an adverse reaction be-
tween epodophyllotoxins and RT in clinical prac-
tice.
33,34 As a consequence of this we chose to
continue IE during RT rather than reduce the inten-
sity of chemotherapy delivered. This approach was
not accompanied by an increase in the severity of
local radiation toxicity. Although this ® nding re-
quires con® rmation in a larger study we suggest that
the combination of IE and RT, at the doses em-
ployed here, does not lead to prohibitive radiation
toxicity.176 S. M. Yule et al.
Our treatment regimen produced an overall DFS
of 57% at a median follow up of 59 months. The
DFS of children who received de® nitive local ther-
apy in this study was superior at 89%. This suggests
that overall treatment ef® cacy may have been com-
promised by the omission of local therapy from
children who exhibited an excellent initial response
to chemotherapy in an effort to reduce long-term
sequelae. The traditional view of de® nitive local
therapy being necessary to eradicate STS is being
challenged in an effort to reduce the long-term
sequelae of treatment. Current SIOP studies reserve
surgery and RT for children with parameningeal
RMS and patients who fail to achieve a CR with
chemotherapy alone. Two of the ® ve children in this
study who did not receive local therapy developed
recurrent disease at the site of the primary tumour.
Only three children, two with orbital RMS, a partic-
ularly favourable prognostic group, and one patient
with retroperitoneal RMS remain disease free after
chemotherapy alone.
The results presented here indicate that, despite
intensifying the chemotherapy of STS, local therapy
remains important in the prevention of locoregional
recurrence. No patient in this study who received
de® nitive surgery or RT to the site of the primary
tumour developed a local recurrence. These results
highlight the dangers of withholding local therapy
on the basis of imaging or repeat biopsy studies
following an apparent CR to primary chemotherapy,
except possibly in the case of orbital RMS. The
decision to avoid RT in children with disease at
other sites, especially elsewhere in the head and
neck, following a CR to chemotherapy should be
taken with caution and should be explored in a
larger multicentre study. It has been suggested that
decisions regarding further therapy are based upon
the initial response to chemotherapy.
26 We would
advocate caution in this respect, particularly in mak-
ing decisions about the necessity for surgery or RT.
Two out of ® ve children in this study who achieved
a CR with chemotherapy, in the absence of local
treatment subsequently developed a locoregional re-
currence and died.
The toxicity of this regimen was considerable.
Two children died from overwhelming sepsis (9%),
a proportion which is consistent with reports from
other studies.
3,35 At the time of introduction of this
treatment regimen ifosfamide-nephrotoxicity was
unknown with early reports of ifosfamide chemo-
therapy in children either failing to recognise renal
toxicity or underestimating its severity. Eight years
later we recognise the importance of this problem.
14
Overall the high incidence of long-term nephrotoxi-
city reported here re¯ ects the large cumulative dose
of ifosfamide administered to many of the patients.
15
In contrast to the relatively high administered
cumulative dose of ifosfamide, the total dose of
doxorubicin was only 240 mg/m
2 thus explaining the
absence of signi® cant cardiotoxicity. A low inci-
dence of signi® cant neurotoxicity was seen and is
consistent with previous reports of the rarity of this
condition in children. Our approach of not altering
subsequent ifosfamide chemotherapy following en-
cephalopathy was justi® ed by a zero recurrence rate.
This report demonstrates that despite intensive
multiagent chemotherapy a high rate of loco-re-
gional recurrence was seen amongst children with
STS who did not receive de® nitive local therapy.
This may have compromised overall survival. Pa-
tients who completed ifosfamide chemotherapy with
appropriate local therapy did well but many have
signi® cant nephrotoxicity. The initial response to IE
was impressive and warrants comparison with other
regimens. We do not advocate the widespread intro-
duction of this treatment protocol because of its
considerable toxicity, in particular its nephrotoxic-
ity. Instead, we believe this report illustrates the
dif® culty in deciding which patients require local
therapy and highlights the dangers of withdrawing
RT in favour of an Impressive response to a new
chemotherapy regimen. Further progress in optimis-
ing treatment regimens for STS will follow the
completion of ongoing multicenter studies.
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